NCT04084951 is a Phase 1 clinical trial of SQZ-PBMC-HPV in Adult Solid Tumor, sponsored by SQZ Biotechnologies.

Who is sponsoring NCT04084951?

NCT04084951 is sponsored by SQZ Biotechnologies.

What drugs are being tested in NCT04084951?

Interventions in NCT04084951: SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab.

What condition does NCT04084951 study?

NCT04084951 studies Adult Solid Tumor.

Is NCT04084951 still recruiting?

NCT04084951 is currently completed. Last updated 14 April 2023.

Last reviewed 2023-04-14 · How we verify

NCT04084951

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Completed Phase 1 Last updated 14 April 2023

What this trial tests

Phase 1 trial testing SQZ-PBMC-HPV in Adult Solid Tumor in 30 participants. Completed in 9 February 2023.

Timeline

28 January 2020

Primary endpoint
9 February 2023

9 February 2023

Quick facts

Lead sponsor	SQZ Biotechnologies
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	28 January 2020
Primary completion	9 February 2023
Estimated completion	9 February 2023
Sites	12 locations across Canada, United States, Germany

Drugs / interventions tested

SQZ-PBMC-HPV — full drug profile →
Atezolizumab (atezolizumab) — full drug profile →
Ipilimumab — full drug profile →
Nivolumab (nivolumab) — full drug profile →

Conditions studied

Adult Solid Tumor — all drugs for Adult Solid Tumor →

Sponsor

SQZ Biotechnologies — full company profile →

Who can join

18 and older, any sex, with Adult Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab or other immune checkpoint inhibitors in HLA-A\*02+ patients with recurrent, locally advanced or metastatic human papillomavirus strain 16 positive (HPV16+) solid tumors. The study includes patients with anal, rectal, cervical, head and neck, penile, vulvar, or vaginal cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Naimi A, Mohammed RN, Raji A, Chupradit S, et al · · 2022 · cited 350× · PMID 35392976 · DOI 10.1186/s12964-022-00854-y
A review of emerging physical transfection methods for CRISPR/Cas9-mediated gene editing.
Fajrial AK, He QQ, Wirusanti NI, Slansky JE, et al · · 2020 · cited 111× · PMID 32373229 · DOI 10.7150/thno.43465
Therapeutic Vaccines for HPV-Associated Malignancies.
Smalley Rumfield C, Roller N, Pellom ST, Schlom J, et al · · 2020 · cited 87× · PMID 33117742 · DOI 10.2147/itt.s273327
Microfluidic and Nanofluidic Intracellular Delivery.
Hur J, Chung AJ. · · 2021 · cited 67× · PMID 34096197 · DOI 10.1002/advs.202004595
Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions.
Tay BQ, Wright Q, Ladwa R, Perry C, et al · · 2021 · cited 42× · PMID 34065557 · DOI 10.3390/vaccines9050535
Novel Antigenic Targets of HPV Therapeutic Vaccines.
Boilesen DR, Nielsen KN, Holst PJ. · · 2021 · cited 28× · PMID 34835193 · DOI 10.3390/vaccines9111262
Therapeutic Vaccination for HPV-Mediated Cancers.
Yan F, Cowell LG, Tomkies A, Day AT. · · 2023 · cited 26× · PMID 36743978 · DOI 10.1007/s40136-023-00443-8
Mechanical stimulation on a microfluidic device to highly enhance small extracellular vesicle secretion of mesenchymal stem cells.
Hao R, Hu S, Zhang H, Chen X, et al · · 2023 · cited 21× · PMID 36619203 · DOI 10.1016/j.mtbio.2022.100527

Verify or expand the search:

Other recruiting trials for Adult Solid Tumor

Currently open trials in the same condition.

NCT07246863 — Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic N · Phase 2 · recruiting
NCT07098988 — Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NS · Phase 2 · recruiting
NCT06059547 — Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer · Phase 2 · active not recruiting
NCT02568267 — Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), · Phase 2 · active not recruiting

Other SQZ Biotechnologies trials

Trials by the same sponsor.

NCT05357898 — Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · terminated
NCT04892043 — Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04084951 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SQZ Biotechnologies
Last refreshed: 14 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04084951.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing